VILYA
Agent26Agent Readiness: 26/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust80Data Trust: 80/100. Top 25%. Measured by StartupHub.ai. Median 61.AI-powered platform for designing novel molecular structures for new medicines.
About
Vilya pioneers computational drug design, creating entirely new de novo macrocycles inspired by biology and designed using AI. Their platform generates, predicts, and validates these molecules in silico, aiming to develop orally bioavailable therapies that combine the selectivity of biologics with the convenience of pills. Vilya serves the pharmaceutical and biotechnology industries by advancing a new class of medicines for previously untreatable diseases.
Listed competitors
Uses AI and automation to industrialize drug discovery and development for rare diseases and cancers.
Specialized services for pharmaceutical and life sciences clients across product development and commercialization.
Diversified biopharmaceutical company focused on rare diseases, generics, and established brands.
Global CRDMO providing integrated R&D and manufacturing services for the pharmaceutical and life sciences industries.
Also in this space
R&D cloud platform for life sciences, enabling scientific innovation and productivity.
Shares BIO + LIFE SCIENCES, Biotech
AI-powered cloud quality management system for life sciences.
Shares BIO + LIFE SCIENCES, Biotech
AI-powered platform for accelerating phylogenetic analysis and evolutionary biology research.
Shares BIO + LIFE SCIENCES, Biotech
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Life Sciences, Biotech
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, HealthTech
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Shares Computational Biology, Life Sciences
Key facts
- Website
- vilya.ai
- Headquarters
- San Francisco, United States
- Founded
- 2022
- Employees
- 47
- Total funding
- $121M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 4 Jun 2024 | Series A | $71M | Arch Venture Partners |
| 29 Aug 2022 | Series A | $50M | Arch Venture Partners |
Tech stack
Detected on vilya.ai, last scanned 29 Oct 2026. Run your own scan
- Frontend
- Svelte, Astro, Tailwind CSS
- CDN
- Cloudflare
- Email provider
- Mimecast
- Email marketing
- Mailgun
VILYA scores 22. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is VILYA trustworthy and reputable?
StartupHub's Data Trust & Reputation score for VILYA is 80 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has VILYA raised?
VILYA has raised a total of $121M in funding. The most recent round on record is Series A.
How many employees does VILYA have?
VILYA has approximately 47 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for VILYA
